IL-ISACA
21.4.2021 15:37:06 CEST | Business Wire | Press release
Emerging technologies are essential to digital transformation and business progress—whether it is blockchain used in supply chains and in the financial industry or artificial intelligence in driving efficiency across sectors. IT professionals seeking to boost their skillset in emerging technologies and ensure their knowledge is up to date can now pursue the Certified in Emerging Technology (CET) certification from global IT professional association and learning organization ISACA.
Established IT professionals, students and recent grads alike can set themselves apart with employers and gain foundational knowledge about the Internet of Things (IoT), artificial intelligence (AI), blockchain and cloud without having prior experience. Along with the recently launched ISACA credential, the Information Technology Certified Associate (ITCA) , the CET certification is unique in offering a vendor-agnostic, hybrid learning model. The CET model features both performance-based and knowledge-based learning—including live labs in a virtual environment—and incorporates a stackable series of certificates.
These certificates, which can be achieved at one’s own pace from anywhere, provide both an examination of each technology and a holistic view of the connections among the emerging technologies, allowing IT professionals to upskill and cross-skill in the following domains:
- Cloud Fundamentals Certificate
- Blockchain Fundamentals Certificate
- IoT Fundamentals Certificate
- Artificial Intelligence Fundamentals Certificate
“It is important for professionals in IT audit, risk, security, governance and privacy to have an understanding of emerging technologies and how they intersect with their work, as well as impact their organizations at a business level,” says David Samuelson, ISACA CEO. “With the new Certified in Emerging Technology certification, ISACA is pleased to offer our global community the tools to gain this knowledge and skillset and continue to take their careers to new heights.”
The CET certification is a good fit for professionals at different levels and job functions—from students and recent graduates wanting to build their résumés, to those already established in roles in governance, risk and compliance; IT audit; network administration; software development; information security; enterprise architecture and business management who want to learn more about emerging technology and how it applies to their roles and organizations.
“Continual up-skilling is a strong signal of professionalism in all IT fields,” said Caitlin McGaw, Principal, Candor McGaw. “Hiring managers are actively looking for people with emerging technology skills. However, since companies are still ramping up these technologies, many professionals have not yet had the chance to gain that experience. Being able to demonstrate the accomplishment of high-quality training and hands-on work with emerging technology will be a substantial competitive advantage for experienced professionals and recent grads alike.”
The CET certification program offers study guides, self-paced training courses, virtual instructor-led training, additional lab packages and exams for each certificate, available at discounted rates to ISACA members. Custom training packages for up-skilling IT teams are also available. Once all four certificate exams are completed, the CET certification is awarded.
This new certification joins an established set of ISACA credentials that have been part of the professional community’s learning journey for years, including Certified Information Systems Auditor (CISA), Certified Information Security Manager (CISM), Certified in Risk and Information Systems Control (CRISC), Certified in the Governance of Enterprise IT (CGEIT), CSX Cybersecurity Practitioner Certification (CSX-P), Certified Data Privacy Solutions Engineer (CDPSE) and ITCA certification.
For more information about the CET certification, visit www.isaca.org/credentialing/cet . More detail about ISACA’s other credentials can be found at www.isaca.org/credentialing , and ISACA publications, audit programs and other resources on emerging tech, including the recently published blockchain framework, are available at www.isaca.org/resources/emerging-technology-resources .
About ISACA
For more than 50 years, ISACA® (www.isaca.org ) equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA is a global professional association and learning organization with more than 150,000 members who work in information security, governance, assurance, risk and privacy, and a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
